🇺🇸 FDA

Intelligence · Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital — phase, modality, and trial IDs.

Programs
1,136

Quick answer

First People's Hospital has 1,136 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. CIK

    The First People's Hospital of Lianyungang

    Lung Adenocarcinoma

    phase 2 mab terminated

    1 trial

  2. CM313 (SC)

    The First People's Hospital of Lianyungang

    Pemphigus Disease

    phase 2 small molecule active

    1 trial

  3. CM336 Injection

    The First People's Hospital of Lianyungang

    Autoimmune Bullous Disease

    phase 2 mab active

    1 trial

  4. CMOP±R

    The First People's Hospital of Lianyungang

    NHL

    phase 2 small molecule active

    1 trial

  5. Cadonilimab

    The First People's Hospital of Lianyungang

    Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  6. Cadonilimab

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Cadonilimab

    The First People's Hospital of Lianyungang

    Immunotherapy

    phase 2 small molecule active

    1 trial

  8. Camrelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  9. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Neoplasms

    phase 2 small molecule active

    1 trial

  10. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Cancer, Nonsmall Cell

    phase 2 small molecule active

    1 trial

  11. Camrelizumab

    The First People's Hospital of Lianyungang

    Locally Advanced or Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  12. Camrelizumab

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 small molecule active

    1 trial

  13. Camrelizumab

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

  14. Camrelizumab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  15. Camrelizumab with vinorelbine and cisplatin

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  16. Cangpo Liujun Prescription

    The First People's Hospital of Lianyungang

    Cancer-Related Fatigue

    phase 2 small molecule active

    1 trial

  17. Capecitabine

    The First People's Hospital of Lianyungang

    Biliary Carcinoma

    phase 2 small molecule active

    1 trial

  18. Capecitabine-Oxaliplatin-Irinotecan Combination

    The First People's Hospital of Lianyungang

    Unresectable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  19. Chidamide

    The First People's Hospital of Lianyungang

    Neuroendocrine Tumors

    phase 2 small molecule active

    2 trials

  20. Chidamide Combined with NKG2D CAR-NK Cell Therapy

    The First People's Hospital of Lianyungang

    HIV (Human Immunodeficiency Virus)

    phase 2 small molecule active

    1 trial

  21. Chidamide combined with Duvillisib

    The First People's Hospital of Lianyungang

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

  22. Cisplatin+Capecitabine+Sintilimab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  23. Clostridium Butyricum Tablets

    The First People's Hospital of Lianyungang

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 2 small molecule active

    1 trial

  24. Combination therapy (COMB)

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  25. Combinations

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  26. Conventional Roux-en-Y Gastrojejunostomy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  27. Cyclophosphamide

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Pediatric

    phase 2 small molecule active

    1 trial

  28. Cyclosporine A

    The First People's Hospital of Lianyungang

    Bone Marrow Failure Disorders

    phase 2 small molecule active

    1 trial

  29. Cytokine-induced killer cells

    The First People's Hospital of Lianyungang

    Ovarian Carcinoma

    phase 2 mab active

    1 trial

  30. Cytokine-induced killer cells

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 mab active

    1 trial

  31. DA-EPOCH

    The First People's Hospital of Lianyungang

    NHL With Hemophagocytic Lymphohistiocytosis

    phase 2 small molecule active

    1 trial

  32. DC-CIK Immunotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 mab active

    1 trial

  33. DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)

    The First People's Hospital of Lianyungang

    Triple-Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  34. DMTs + taurine

    The First People's Hospital of Lianyungang

    Multiple Sclerosis (MS) Relapsing Remitting

    phase 2 small molecule active

    1 trial

  35. Dalpiciclib

    The First People's Hospital of Lianyungang

    Early Breast Cancer

    phase 2 small molecule active

    1 trial

  36. Darolutamide+ADT

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  37. Deep-sea fish oil

    The First People's Hospital of Lianyungang

    Radiation Toxicity

    phase 2 small molecule active

    1 trial

  38. Dermatophagoides Farinae Drops Group 1

    The First People's Hospital of Lianyungang

    Atopic Dermatitis

    phase 2 mab completed

    1 trial

  39. Determine the ED50 and ED95 of esketamine

    The First People's Hospital of Lianyungang

    Intrauterine Polyp

    phase 2 small molecule active

    1 trial

  40. Dexamethasone

    The First People's Hospital of Lianyungang

    Precursor B-Cell Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  41. Disitamab Vedotin

    The First People's Hospital of Lianyungang

    HER2-positive Gastric Cancer

    phase 2 small molecule active

    1 trial

  42. Disitamab Vedotin (RC48)

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  43. Doxorubicin liposome

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  44. Dragon Boat Training

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  45. Drug-coated balloon angioplasty

    The First People's Hospital of Lianyungang

    Vertebral Artery Stenosis

    phase 2 other active

    1 trial

  46. EGFR Antibody

    The First People's Hospital of Lianyungang

    Nasopharyngeal Cancinoma (NPC)

    phase 2 small molecule active

    1 trial

  47. Edaravone Dexborneol

    The First People's Hospital of Lianyungang

    Stroke, Ischemic

    phase 2 small molecule active

    1 trial

  48. Ejiao compound

    The First People's Hospital of Lianyungang

    Postpartum Anemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

1,136 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.